PhenylpiracetamvsSulbutiamine

Phenylpiracetam modulates AMPA and NMDA glutamate receptors like other racetams through positive allosteric modulation. The phenyl group confers additional affinity for dopamine (DAT) and norepinephrine (NET) transporters, acting as a weak reuptake inhibitor and increasing synaptic catecholamine availability — providing stimulatory and motivational effects. It binds to α4β2 and α7 nicotinic acetylcholine receptors as a positive allosteric modulator, enhancing cholinergic transmission in the prefrontal cortex and hippocampus. The phenyl moiety improves blood-brain barrier penetration via increased lipophilicity and potentially P-glycoprotein substrate properties. Downstream effects include enhanced CREB phosphorylation and BDNF expression. The combination of glutamatergic, dopaminergic, noradrenergic, and cholinergic modulation produces synergistic cognitive enhancement.

Sulbutiamine consists of two thiamine (vitamin B1) molecules connected by a disulfide bridge, conferring lipophilicity and efficient blood-brain barrier penetration via passive diffusion. In the brain, it is hydrolyzed to thiamine and increases thiamine diphosphate (TDP) levels—the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase, enzymes critical for glucose metabolism and the Krebs cycle. Sulbutiamine upregulates D1 dopamine receptors in the prefrontal cortex, possibly through reduced receptor internalization or increased expression. It modulates glutamatergic transmission (affecting NMDA/AMPA receptor function) and enhances cholinergic transmission. The anti-fatigue and memory-enhancing effects likely stem from improved neuronal glucose oxidation, increased ATP production, and enhanced dopaminergic and cholinergic tone in cognitive circuits.